Tamborlane, William
Shehadeh, Naim
Funding for this research was provided by:
AstraZeneca
Article History
Received: 20 June 2023
Accepted: 8 August 2023
First Online: 5 September 2023
Declarations
:
: William Tamborlane is a consultant for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Medtronic Diabetes. Naim Shehadeh has received grants for medical research from Novo Nordisk; has participated in a data safety monitoring board or advisory board for Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, AstraZeneca and Abbott; has received consulting fees and payment or honoraria from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, AstraZeneca, and Abbott; and has received support for attending meetings or travel from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, and AstraZeneca.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.